Avadel Pharmaceuticals plc
US ˙ NasdaqGM ˙ US05337M1045

Introduction

This page provides a comprehensive analysis of the known insider trading history of Craig R Stapleton. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Craig R Stapleton has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:AVDL / Avadel Pharmaceuticals plc Director 378,228
US:ANF / Abercrombie & Fitch Co. Director 0
US:RETA / Reata Pharmaceuticals Inc - Class A 32,864
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Craig R Stapleton. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases AVDL / Avadel Pharmaceuticals plc - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AVDL / Avadel Pharmaceuticals plc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2017-12-15 AVDL STAPLETON CRAIG R 70,000 8.6710 70,000 8.6710 606,970 39 11.7000 212,030 34.93
2017-12-15 AVDL STAPLETON CRAIG R 70,000 8.6710 70,000 8.6710 606,970
2017-09-12 AVDL STAPLETON CRAIG R 20,000 9.5180 20,000 9.5180 190,360
2017-05-22 AVDL STAPLETON CRAIG R 16,900 9.7600 16,900 9.7600 164,944
2017-05-19 AVDL STAPLETON CRAIG R 3,100 9.8300 3,100 9.8300 30,473
2017-05-18 AVDL STAPLETON CRAIG R 11,013 9.9800 11,013 9.9800 109,910
2016-11-29 FLML STAPLETON CRAIG R 10,000 10.8500 10,000 10.8500 108,500
2016-11-28 FLML STAPLETON CRAIG R 10,000 10.7370 10,000 10.7370 107,370
2016-09-01 FLML STAPLETON CRAIG R 10,000 13.5190 10,000 13.5190 135,190
2016-08-26 FLML STAPLETON CRAIG R 10,878 13.8300 10,878 13.8300 150,443
2016-08-26 FLML STAPLETON CRAIG R 9,122 13.6700 9,122 13.6700 124,698
2016-05-16 FLML STAPLETON CRAIG R 2,415 9.2500 2,415 9.2500 22,339
2016-05-13 FLML STAPLETON CRAIG R 24,813 9.2110 24,813 9.2110 228,553
2016-03-14 FLML STAPLETON CRAIG R 100,000 10.3940 100,000 10.3940 1,039,400

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AVDL / Avadel Pharmaceuticals plc Insider Trades
Insider Sales AVDL / Avadel Pharmaceuticals plc - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AVDL / Avadel Pharmaceuticals plc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2017-11-27 AVDL STAPLETON CRAIG R 254,265 9.3510 254,265 9.3510 2,377,632 358 2.9400 -1,630,093 -68.56

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AVDL / Avadel Pharmaceuticals plc Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Craig R Stapleton as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2018-08-02 2018-08-01 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 27,900 378,228 7.96
2018-07-11 2018-07-09 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 57,315 350,328 19.56
2018-03-02 2017-06-28 4/A AVDL AVADEL PHARMACEUTICALS PLC
Stock Option (right to buy)
A - Award 35,000 35,000 10.51 367,850 367,850
2017-12-19 2017-12-15 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 70,000 180,000 63.64 8.67 606,970 1,560,780
2017-12-19 2017-12-15 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 70,000 180,000 63.64 8.67 606,970 1,560,780
2017-12-19 2017-12-15 4/A AVDL AVADEL PHARMACEUTICALS PLC
ADSs
P - Purchase 70,000 180,000 63.64 8.67 606,970 1,560,780
2017-12-19 2017-12-15 4/A AVDL AVADEL PHARMACEUTICALS PLC
ADSs
P - Purchase 70,000 323,413 27.62 8.67 606,970 2,804,314
2017-11-29 2017-11-27 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
S - Sale -254,265 253,413 -50.08 9.35 -2,377,632 2,369,665
2017-09-14 2017-09-12 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
P - Purchase 20,000 110,000 22.22 9.52 190,360 1,046,980
2017-06-30 2017-06-28 4 AVDL AVADEL PHARMACEUTICALS PLC
Stock Option (right to buy)
A - Award 30,000 30,000 10.51 315,300 315,300
2017-06-16 2017-06-15 4 ANF ABERCROMBIE & FITCH CO /DE/
Restricted Stock Unit
M - Exercise -8,043 0 -100.00
2017-06-16 2017-06-15 4 ANF ABERCROMBIE & FITCH CO /DE/
Phantom Stock
M - Exercise 8,043 32,660 32.67
2017-05-22 2017-05-22 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
P - Purchase 16,900 90,000 23.12 9.76 164,944 878,400
2017-05-22 2017-05-19 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
P - Purchase 3,100 73,100 4.43 9.83 30,473 718,573
2017-05-22 2017-05-18 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
P - Purchase 11,013 70,000 18.67 9.98 109,910 698,600
2017-05-18 2017-05-17 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 12,100 58,987 25.81 9.95 120,393 586,909
2017-05-18 2017-05-16 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 3,470 46,887 7.99 10.00 34,700 468,870
2017-05-16 2017-05-15 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 311 43,417 0.72 10.00 3,110 434,170
2017-05-16 2017-05-12 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 3,106 43,106 7.76 10.00 31,060 431,060
2017-04-05 2017-04-04 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 15,000 507,678 3.04 9.58 143,643 4,861,626
2017-02-24 2017-01-03 4/A AVDL AVADEL PHARMACEUTICALS PLC
Warrants (right to buy)
A - Award 117,449 117,449
2017-02-24 2017-01-03 4/A AVDL AVADEL PHARMACEUTICALS PLC
Warrants (right to buy)
A - Award 117,449 117,449
2017-02-24 2017-01-03 4/A AVDL AVADEL PHARMACEUTICALS PLC
Warrants (right to buy)
A - Award 100,000 100,000
2017-02-24 2017-01-03 4/A AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 16,200 16,200
2017-02-24 2017-01-03 4/A AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 40,000 40,000
2017-02-24 2017-01-03 4/A AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 492,678 492,678
2017-01-13 2017-01-03 4/A AVDL AVADEL PHARMACEUTICALS PLC
Warrants (right to buy)
A - Award 117,449 117,449
2017-01-13 2017-01-03 4/A AVDL AVADEL PHARMACEUTICALS PLC
Warrants (right to buy)
A - Award 100,000 100,000
2017-01-13 2017-01-03 4/A AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 16,200 16,200
2017-01-13 2017-01-03 4/A AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 40,000 40,000
2017-01-13 2017-01-03 4/A AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 492,678 492,678
2017-01-03 2017-01-03 4 AVDL AVADEL PHARMACEUTICALS PLC
Warrants (right to buy)
A - Award 117,449 117,449
2017-01-03 2017-01-03 4 AVDL AVADEL PHARMACEUTICALS PLC
Warrants (right to buy)
A - Award 100,000 100,000
2017-01-03 2017-01-03 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 16,200 16,200
2017-01-03 2017-01-03 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 40,000 40,000
2017-01-03 2017-01-03 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
A - Award 492,678 492,678
2017-01-03 2016-12-31 4 AVDL AVADEL PHARMACEUTICALS PLC
Warrants (right to buy)
D - Sale to Issuer -117,449 0 -100.00
2017-01-03 2016-12-31 4 AVDL AVADEL PHARMACEUTICALS PLC
Warrants (right to buy)
D - Sale to Issuer -100,000 0 -100.00
2017-01-03 2016-12-31 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
D - Sale to Issuer -16,200 0 -100.00
2017-01-03 2016-12-31 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
D - Sale to Issuer -40,000 0 -100.00
2017-01-03 2016-12-31 4 AVDL AVADEL PHARMACEUTICALS PLC
ADSs
D - Sale to Issuer -492,678 0 -100.00
2016-12-20 2016-12-19 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
G - Gift 16,200 16,200
2016-12-20 2016-12-19 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
G - Gift 13,500 40,000 50.94
2016-12-20 2016-12-19 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
G - Gift -8,100 26,500 -23.41
2016-12-20 2016-12-19 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
G - Gift -8,100 26,500 -23.41
2016-12-20 2016-12-19 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
G - Gift -5,400 34,600 -13.50
2016-12-20 2016-12-19 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
G - Gift -5,400 34,600 -13.50
2016-12-20 2016-12-19 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
G - Gift -13,500 492,678 -2.67
2016-11-30 2016-11-29 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
P - Purchase 10,000 40,000 33.33 10.85 108,500 434,000
2016-11-30 2016-11-28 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
P - Purchase 10,000 30,000 50.00 10.74 107,370 322,110
2016-09-06 2016-09-01 4 ANF ABERCROMBIE & FITCH CO /DE/
Class A Common Stock
P - Purchase 10,000 57,398 21.10 17.65 176,500 1,013,075
2016-09-06 2016-09-01 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
P - Purchase 10,000 519,678 1.96 13.52 135,190 7,025,527
2016-08-29 2016-08-26 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
P - Purchase 9,122 20,000 83.86 13.67 124,698 273,400
2016-08-29 2016-08-26 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
P - Purchase 10,878 10,878 13.83 150,443 150,443
2016-06-20 2016-06-16 4 ANF ABERCROMBIE & FITCH CO /DE/
Restricted Stock Unit
M - Exercise -5,391 0 -100.00
2016-06-20 2016-06-16 4 ANF ABERCROMBIE & FITCH CO /DE/
Restricted Stock Unit
A - Award 8,043 8,043
2016-06-20 2016-06-16 4 ANF ABERCROMBIE & FITCH CO /DE/
Phantom Stock
M - Exercise 5,391 23,242 30.20
2016-06-13 2016-06-09 4 RETA REATA PHARMACEUTICALS INC
Class A common stock
J - Other -420,000 32,864 -92.74
2016-06-13 3 RETA REATA PHARMACEUTICALS INC
Class A common stock
905,728
2016-06-13 3 RETA REATA PHARMACEUTICALS INC
Class A common stock
905,728
2016-06-13 3 RETA REATA PHARMACEUTICALS INC
Class A common stock
905,728
2016-05-16 2016-05-16 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
P - Purchase 2,415 509,678 0.48 9.25 22,339 4,714,522
2016-05-16 2016-05-13 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
P - Purchase 24,813 507,263 5.14 9.21 228,553 4,672,399
2016-03-16 2016-03-14 4 FLML FLAMEL TECHNOLOGIES SA
ADSs
P - Purchase 100,000 482,450 26.15 10.39 1,039,400 5,014,585
2016-01-04 3 FLML FLAMEL TECHNOLOGIES SA
ADSs
764,900
2016-01-04 3 FLML FLAMEL TECHNOLOGIES SA
ADSs
764,900
2015-06-29 2015-06-22 4 ANF ABERCROMBIE & FITCH CO /DE/
Class A Common Stock
P - Purchase 10,000 47,398 26.74 22.42 224,200 1,062,663
2015-06-22 2015-06-18 4 ANF ABERCROMBIE & FITCH CO /DE/
Restricted Stock Unit
M - Exercise -3,000 0 -100.00
2015-06-22 2015-06-18 4 ANF ABERCROMBIE & FITCH CO /DE/
Restricted Stock Unit
A - Award 5,391 5,391
2015-06-22 2015-06-18 4 ANF ABERCROMBIE & FITCH CO /DE/
Phantom Stock
M - Exercise 3,000 17,137 21.22
2014-06-23 2014-06-20 4 ANF ABERCROMBIE & FITCH CO /DE/
Restricted Stock Unit
M - Exercise -3,000 0 -100.00
2014-06-23 2014-06-20 4 ANF ABERCROMBIE & FITCH CO /DE/
Phantom Stock
M - Exercise 3,000 13,789 27.81
2014-06-23 2014-06-19 4 ANF ABERCROMBIE & FITCH CO /DE/
Restricted Stock Unit
A - Award 3,000 3,000
2014-06-02 2014-05-30 4 ANF ABERCROMBIE & FITCH CO /DE/
Class A Common Stock
P - Purchase 10,000 37,398 36.50 37.30 373,000 1,394,945
2013-07-01 2013-06-25 4 ANF ABERCROMBIE & FITCH CO /DE/
Class A Common Stock
P - Purchase 5,000 27,398 22.32 43.98 219,900 1,204,961
2013-07-01 2013-06-25 4 ANF ABERCROMBIE & FITCH CO /DE/
Class A Common Stock
P - Purchase 5,000 22,398 28.74 44.05 220,250 986,632
2013-06-21 2013-06-20 4 ANF ABERCROMBIE & FITCH CO /DE/
Restricted Stock Unit
A - Award 3,000 3,000
2013-06-17 2013-06-14 4 ANF ABERCROMBIE & FITCH CO /DE/
Restricted Stock Unit
M - Exercise -3,930 0 -100.00
2013-06-17 2013-06-14 4 ANF ABERCROMBIE & FITCH CO /DE/
Phantom Stock
M - Exercise 3,930 10,585 59.05
2012-06-19 2012-06-18 4 ANF ABERCROMBIE & FITCH CO /DE/
Restricted Stock Unit
M - Exercise -3,000 0 -100.00
2012-06-19 2012-06-18 4 ANF ABERCROMBIE & FITCH CO /DE/
Phantom Stock
M - Exercise 3,000 6,551 84.48
2012-06-18 2012-06-14 4 ANF ABERCROMBIE & FITCH CO /DE/
Restricted Stock Unit
A - Award 3,930 3,930
2012-05-23 2012-05-22 4 ANF ABERCROMBIE & FITCH CO /DE/
Class A Common Stock
P - Purchase 10,000 17,398 135.17 35.43 354,295 616,402
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)